Literature DB >> 31221810

The global prevalence of latent tuberculosis: a systematic review and meta-analysis.

Adam Cohen1,2, Victor Dahl Mathiasen3,4,2, Thomas Schön5,6, Christian Wejse7,8,9.   

Abstract

In 1999, the World Health Organization (WHO) estimated that one-third of the world's population had latent tuberculosis infection (LTBI), which was recently updated to one-fourth. However, this is still based on controversial assumptions in combination with tuberculin skin test (TST) surveys. Interferon-γ release assays (IGRAs) with a higher specificity than TST have since been widely implemented, but never used to estimate the global LTBI prevalence.We conducted a systematic review and meta-analysis of LTBI estimates based on both IGRA and TST results published between 2005 and 2018. Regional and global estimates of LTBI prevalence were calculated. Stratification was performed for low, intermediate and high TB incidence countries and a pooled estimate for each area was calculated using a random effects model.Among 3280 studies screened, we included 88 studies from 36 countries with 41 IGRA (n=67 167) and 67 TST estimates (n=284 644). The global prevalence of LTBI was 24.8% (95% CI 19.7-30.0%) and 21.2% (95% CI 17.9-24.4%), based on IGRA and a 10-mm TST cut-off, respectively. The prevalence estimates correlated well to WHO incidence rates (Rs=0.70, p<0.001).In the first study of the global prevalence of LTBI derived from both IGRA and TST surveys, we found that one-fourth of the world's population is infected. This is of relevance, as both tests, although imperfect, are used to identify individuals eligible for preventive therapy. Enhanced efforts are needed targeting the large pool of latently infected individuals, as this constitutes an enormous source of potential active tuberculosis.
Copyright ©ERS 2019.

Entities:  

Year:  2019        PMID: 31221810     DOI: 10.1183/13993003.00655-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  78 in total

1.  Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study.

Authors:  Shu-Yung Lin; Jia-Yih Feng; Chih-Yuan Lee; Yi-Chih Lin; Yu-Hsiang Chou; Kuan-Yin Lin; Yu-Feng Wei; Shu-Wen Lin; Chin-Hao Chang; Ping-Huai Wang; Chin-Chung Shu; Jann-Yuan Wang; Chong-Jen Yu
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Risk of Serotonin Syndrome with Isoniazid.

Authors:  Michael E O'Brien; Ronak G Gandhi; Camille N Kotton; Meagan L Adamsick
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

3.  Structure-activity relationship studies on 2,5,6-trisubstituted benzimidazoles targeting Mtb-FtsZ as antitubercular agents.

Authors:  Krupanandan Haranahalli; Simon Tong; Saerom Kim; Monaf Awwa; Lei Chen; Susan E Knudson; Richard A Slayden; Eric Singleton; Riccardo Russo; Nancy Connell; Iwao Ojima
Journal:  RSC Med Chem       Date:  2020-10-16

4.  QuantiFERON-TB Gold Plus with Chemiluminescence Immunoassay: Do We Need a Higher Cutoff?

Authors:  Francesco Bisognin; Giulia Lombardi; Maria Carla Re; Paola Dal Monte
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

5.  Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection.

Authors:  Wenxi Xu; Laura M Snell; Mengdi Guo; Giselle Boukhaled; Bethany L Macleod; Ming Li; Michael V Tullius; Cynthia J Guidos; Ming-Sound Tsao; Maziar Divangahi; Marcus A Horwitz; Jun Liu; David G Brooks
Journal:  Immunity       Date:  2021-01-29       Impact factor: 31.745

6.  Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung.

Authors:  Paul Ogongo; Liku B Tezera; Amanda Ardain; Shepherd Nhamoyebonde; Duran Ramsuran; Alveera Singh; Abigail Ng'oepe; Farina Karim; Taryn Naidoo; Khadija Khan; Kaylesh J Dullabh; Michael Fehlings; Boon Heng Lee; Alessandra Nardin; Cecilia S Lindestam Arlehamn; Alessandro Sette; Samuel M Behar; Adrie Jc Steyn; Rajhmun Madansein; Henrik N Kløverpris; Paul T Elkington; Alasdair Leslie
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 19.456

7.  Comparison of a mycobacterial phage assay to detect viable Mycobacterium avium subspecies paratuberculosis with standard diagnostic modalities in cattle with naturally infected Johne disease.

Authors:  Robert J Greenstein; Liya Su; Irene R Grant; Antonio C G Foddai; Amy Turner; Jason S Nagati; Sheldon T Brown; Judith R Stabel
Journal:  Gut Pathog       Date:  2021-05-06       Impact factor: 4.181

8.  A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.

Authors:  Thomas E J Chavas; Fang-Yi Su; Selvi Srinivasan; Debashish Roy; Brian Lee; Lara Lovelace-Macon; Guilhem F Rerolle; Elaine Limqueco; Shawn J Skerrett; Daniel M Ratner; T Eoin West; Patrick S Stayton
Journal:  J Control Release       Date:  2020-11-19       Impact factor: 9.776

9.  Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis.

Authors:  Kieran Rustage; Jessica Lobe; Sally E Hayward; Kristina L Kristensen; Ioana Margineanu; Ymkje Stienstra; Delia Goletti; Dominik Zenner; Teymur Noori; Manish Pareek; Christina Greenaway; Jon S Friedland; Laura B Nellums; Sally Hargreaves
Journal:  Lancet Infect Dis       Date:  2021-08-04       Impact factor: 25.071

10.  Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection.

Authors:  Elisa Petruccioli; Teresa Chiacchio; Assunta Navarra; Valentina Vanini; Gilda Cuzzi; Claudia Cimaglia; Luigi Ruffo Codecasa; Carmela Pinnetti; Niccolò Riccardi; Fabrizio Palmieri; Andrea Antinori; Delia Goletti
Journal:  J Infect       Date:  2020-02-22       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.